Expected PSA Increase with Age

Age-Specific PSA Reference Ranges

• The American Urological Association suggests that age-specific PSA reference ranges vary by ethnicity, with median values of 0.7 ng/mL for men in their 40s, 0.9 ng/mL for men in their 50s, 1.2 ng/mL for men in their 60s, and 1.5 ng/mL for men in their 70s 1, 2
• For White Men, the age-specific PSA reference ranges are: 0-2.5 ng/mL for 40-49 years, 0-3.5 ng/mL for 50-59 years, 0-4.5 ng/mL for 60-69 years, and 0-6.5 ng/mL for 70-79 years 1
• For African-American Men, the age-specific PSA reference ranges are: 0-2.0 ng/mL for 40-49 years, 0-4.0 ng/mL for 50-59 years, 0-4.5 ng/mL for 60-69 years, and 0-5.5 ng/mL for 70-79 years 1
• For Asian-American Men, the age-specific PSA reference ranges are: 0-2.0 ng/mL for 40-49 years, 0-3.0 ng/mL for 50-59 years, 0-4.0 ng/mL for 60-69 years, and 0-5.0 ng/mL for 70-79 years 1

PSA Velocity with Age

• Age-adjusted PSA velocity thresholds that may warrant further investigation are: 0.25 ng/mL/year in men ages 40-59, 0.50 ng/mL/year in men ages 60-69, and 0.75 ng/mL/year in men over 70 1, 2

Risk Assessment and Screening Considerations

• Men with PSA levels below the median (<1 ng/mL) at age 60 have only a 0.5% risk of metastases and 0.2% risk of prostate cancer death, according to the National Comprehensive Cancer Network 3
• Men aged 75 years or older with PSA less than 3.0 ng/mL are unlikely to die from prostate cancer and may safely discontinue screening, as recommended by the National Comprehensive Cancer Network 3, 4

Important Caveats

• Laboratory variability in PSA testing can range from 20-25% depending on standardization method, highlighting the importance of using the same assay for longitudinal monitoring 2
• Assays using the World Health Organization standard yield results 20-25% lower than those using the Hybritech standard, emphasizing the need for standardization 2
• It is crucial to use the same assay for longitudinal monitoring as PSA assays are not interchangeable, and consider confirming an abnormal PSA before proceeding to biopsy 2

Prostate-Specific Antigen Screening Guidelines

Screening Recommendations by Age

• The National Comprehensive Cancer Network recommends baseline PSA testing to begin at age 45-50 years for most men, with strongest evidence supporting testing at age 55, and men with PSA ≥1.0 ng/mL should undergo repeat testing at 1-2 year intervals, while those with PSA <1.0 ng/mL can be retested at 2-4 year intervals 5, 6, 7
• For men aged 55-70 years, the European Randomized Study of Screening for Prostate Cancer (ERSPC) and Göteborg trials demonstrated decreased disease-specific mortality, providing strong evidence for mortality benefit from PSA screening 5, 6
• Screening decisions for men aged 70-75 years should be highly individualized based on health status and life expectancy, and men with excellent health, absence of comorbidities, and family longevity may benefit from continued screening 7, 8

PSA Velocity and Risk Stratification

• Men with PSA velocity >2.0 ng/mL/year in the year before diagnosis have approximately 10-fold greater risk of death from prostate cancer after treatment 8
• The American College of Physicians and other organizations recommend using age-adjusted PSA velocity thresholds to guide further investigation, although specific thresholds are not provided in the cited references 8

Age‑Adjusted PSA Reference Ranges and Interpretation for Men Aged 70‑79

Reference Ranges by Ethnicity

• The American Urological Association recommends the following upper limits of normal PSA for men aged 70‑79: 0‑6.5 ng/mL for White men, 0‑5.5 ng/mL for African‑American men, and 0‑5.0 ng/mL for Asian‑American men. 9

Median PSA Benchmark

• In men in their 70s, the median PSA is approximately 1.5 ng/mL; half of healthy men without prostate cancer have values below this level, making values markedly above the median more concerning even when they fall within the upper‑limit range. 9

PSA Velocity Threshold

• For men over 70, an increase of ≥0.75 ng/mL per year (calculated from at least three PSA measurements over 18 months) is considered worrisome and warrants further evaluation. 9

PSA Variability and Repeat Testing

• PSA measurements can vary by 20‑25 % between assays; values exceeding the age‑specific upper limit should be confirmed with repeat testing using the same laboratory and assay before proceeding to advanced imaging or biopsy. [9][10]

Non‑Cancer Causes of PSA Elevation

*These conditions can increase PSA independent of malignancy. [9][10]

PSA‑Lowering Medications

• Finasteride or dutasteride therapy reduces PSA concentrations by roughly 50 %; PSA values obtained while on these agents should be interpreted accordingly. 10

Laboratory Assay Standardization

• Serial PSA measurements must be performed in the same laboratory using the same assay, as different assays are not interchangeable. [9][10]
• Assays calibrated to the WHO standard yield results that are 20‑25 % lower than those calibrated to the Hybritech standard. 10

Age‑Adjusted PSA Guidelines and Clinical Decision‑Making

PSA Kinetics and Adjunctive Biomarkers

• PSA velocity assessment requires at least three PSA measurements spanning a minimum of 18 months before it can be used to inform biopsy decisions. (National Comprehensive Cancer Network) 11
• A percent free PSA < 25 % identifies approximately 95 % of prostate cancers while substantially reducing unnecessary biopsies. (National Comprehensive Cancer Network) 11
• The 4Kscore test is recommended as an additional risk stratification tool for men with PSA 3–10 ng/mL who have not yet undergone biopsy. (National Comprehensive Cancer Network) 11
• For patients with a prior negative biopsy, PCA3 testing may be considered to improve detection of clinically significant disease. (National Comprehensive Cancer Network) 11

Guideline Society Recommendations

• The NCCN (2015) states that the precise role of age‑specific PSA cut‑offs in early detection is uncertain and it makes no formal recommendation for routine use of these ranges. (National Comprehensive Cancer Network) 11
• The American Cancer Society advises maintaining the traditional PSA threshold of 4.0 ng/mL for average‑risk men, but recommends individualized risk assessment for men whose PSA lies between 2.5 ng/mL and 4.0 ng/mL. (American Cancer Society) 12
• This individualized approach seeks to balance the higher cancer detection rate achieved with lower thresholds against the increased risk of false‑positive results and overdiagnosis. (American Cancer Society) 12

Special Populations

• In African‑American men, PSA test positivity, cancer detection rates, and positive predictive values are markedly higher; for ages 70‑79, positivity can reach 54 %, detection 25 %, and PPV 59 % when using a 4.0 ng/mL cut‑off. (American Cancer Society) 12
• Among men with a positive family history, PSA positivity ranges from 9 % to 11 %, cancer detection is ≈3 %, and PPV varies widely (28 %–94 %) at the 4.0 ng/mL threshold; lowering the threshold to 2.0–2.5 ng/mL raises PPV to 38 %–43 %. (American Cancer Society) 12

Discontinuation of Screening in Older Men

• Men aged ≥ 75 years with PSA < 3.0 ng/mL have a very low likelihood of dying from prostate cancer and may safely stop PSA screening. (National Comprehensive Cancer Network, 2014) 13
• Screening at any age should be limited to individuals whose life expectancy exceeds 10–15 years. (National Comprehensive Cancer Network, 2014) 13